Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

Abstract Background The high incidence and mortality of lung cancer have seriously affected human life and health. Nivolumab is a monoclonal antibody that can inhibit programmed death 1 (PD-1) and Ipilimumab is a monoclonal antibody against CTLA-4(cytotoxic T lymphocyte-associated antigen 4), both o...

Full description

Bibliographic Details
Main Authors: Huihui Jiang, Aiqun Xu, Wanli Xia, Xingyuan Xia, Pulin Li, Binbin Zhang, Ke Zhu, Sijing Zhou, Ran Wang
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Cancer Cell International
Subjects:
Antitumor drugs
Ipilimumab
Lung cancer
Nivolumab
Immunotherapy
Online Access:https://doi.org/10.1186/s12935-021-02100-w

Internet

https://doi.org/10.1186/s12935-021-02100-w

Similar Items